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Abstract: Eleven compounds belonging to the chalcone family were tested for their 
ability to activate and subsequently desensitize the rat transient receptor potential 
ankyrin 1 cation channel, subfamily A, member 1 (TRPA1) in a heterologous 
expression system. Four of the tested compounds were more potent than the TRPA1 
agonist mustard oil, and showed also a strong desensitizing effect. Some chalcone 
compounds were not pungent in the eye-wiping assay and quite remarkably inhibited 
in a long-lasting and dose-dependent manner the mustard oil-induced response in the 
formalin test. Chalcones can be considered as novel candidates for the development 
of anti-hyperalgesic preparations based on TRPA1 desensitization. 
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1. INTRODUCTION 
 Chalcones are naturally-occurring compounds which 
display a wide range of biological properties. Chalcone (1,3-
diphenyl-2E-propene-1-one) is an open chain intermediate 
precursor in the synthesis of flavones [1]. It contains two 
aromatic rings connected by a α-β-unsaturated ketone system 
[2]. The most important sources of chalcones are plant 
extracts, which are widely used in traditional Chinese 
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Medicine, although the potential uses of this family of 
compounds have not been fully explored [3].  
 Synthetic chalcones and chalcone derivatives show a 
wide range of biological activities with therapeutic interest 
[for reviews see 3, 4]. One of the most studied applications 
of these compounds is as anticancer agents [5, 6], and a 
series of chalcone derivatives with excellent antitumor 
activity have been patented [3]. Very interestingly, 
compounds bearing electron-withdrawing groups (NO2 or 
CN) on the ring near the α-β-unsaturation of chalcones were 
the most potent [7]. Chalcone analogs bearing an additional 
α,β-unsaturated arylketone were active against the resistant 
T-47D breast cancer cells [8]. The induction of apoptosis by 
intrinsic pathways, alterations in the cellular levels of Bcl-2 
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family proteins, upregulation of p53 and PUMA, inhibition 
of nuclear factor-κB (NF-κB) and Akt, and blockage of 
oxidative stress might represent possible mechanisms [9-14]. 
The role of some chalcones as anti-inflammatory agents is 
summarized in a comprehensive review [15]. Several pure 
chalcones have been approved for clinical use and tested in 
humans, and are well-tollerated [16].  
 Despite the impressive pharmacological potential of 
chalcones, their mechanism of action has not been fully 
clarified. The presence of a double bond in conjugation with 
a carbonyl group is believed to be responsible for the 
biological activities of chalcones. The α,β-unsaturated 
carbonyl compounds, by being Michael acceptors and 
capable of trapping thiols, represent an important mechanism 
of bioactivity [17]. Nucleophilic cysteines and lysines 
located in the cytosolic N-terminus of the transient receptor 
potential ankyrin 1 cation channel, subfamily A, member 1 
(TRPA1) undergo covalent attack by reactive electrophilic 
chemicals, leading to formation of Michael adducts and 
allosteric opening of the channel [18, 19]. TRPA1 agonists 
such as allyl isothiocyanate (mustard oil, MO) and several 
α,β-unsaturated aldehydes such as formaldehyde and its 
aqueous solution, formalin, directly activate TRPA1 and are 
widely used for testing analgesic compounds [20].  
 As the above data suggest that calchones might modulate 
TRPA1 activity we investigated 11 novel chalcone 
derivatives for TRPA1 activity as well as anti-nociceptive 
and anti-inflammatory activity in vivo. . 
2. MATERIAL AND METHODS 
2.1. Chemistry 
 All reagents and solvents were of the highest commercial 
quality available and used as received. Chalcones were 
synthesized as follows: an aqueous solution of sodium 
hydroxide (30%, 25 mL) was slowly added to a methanol 
solution (30 mL) of the appropriate acetophenone (5.0 mmol). 
After the solution had been cooled to room temperature, the 
appropriate benzaldehyde (6.0 mmol) was added. The 
mixture was stirred at room temperature overnight and was 
then poured into water (100 mL). The obtained solid was 
filtered, washed with water until reaching neutral pH and 
recrystallized from ethanol. The chemical structure was 
confirmed base on reported data (references [21-27] in  
Table 1). 
2.2. Cell Cultures 
 HEK-293 (human embryonic kidney) and HEK-293 
heterologously transfected with recombinant rat TRPA1 
selected by G-418 (Geneticin; 600 µg/ml), were grown as 
monolayers on 100 mm diameter Petri dishes in Minimum 
Essential Medium supplemented with non-essential amino 
acids, 10% fetal bovine serum and 2 mM glutamine, and 
maintained under 5% CO2 at 37°C. HEK-293 cells were 
purchased from Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (DSMZ, Braunschweig, Berlin, 
Germany). Cell culture medium and supplements were from 
Invitrogen. 
 
2.3. Assay of TRPA1-mediated Elevation of Intracellular 
[Ca2+] 
 Compound effects on intracellular Ca2+ concentration 
([Ca2+]i) were determined using the selective intracellular 
fluorescent probe Fluo-4. On the day of the experiment, cells 
were loaded for 1 h at room temperature with Fluo-4-AM 
methyl ester (4 µM in dimethyl sulfoxide containing 0.02% 
Pluronic F-127, Invitrogen) in Minimal Essential Medium 
without fetal bovine serum, then washed twice in a buffer 
containing 145 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2, 1.2 
mM MgCl2, 10 mM D-glucose and 10 mM HEPES, pH 7.4, 
resuspended in the same buffer, and transferred (about 
100,000 cells) to the quartz cuvette of the spectrofluorimeter 
(Perkin-Elmer LS50B equipped with PTP-1 Fluorescence 
Peltier System; PerkinElmer Life and Analytical Sciences, 
Waltham, MA, USA) under continuous stirring. The changes 
in [Ca2+]i were determined before and after addition of 
various concentrations of test compounds by measuring cell 
fluorescence (λEX = 488 nm, λEM = 516 nm) at 25 °C. Curve 
fitting (sigmoidal dose-response variable slope) and 
parameter estimation were performed with GraphPad Prism® 
(GraphPad Software Inc., San Diego, CA). Potency was 
expressed as the concentration of test compound exerting a 
half-maximal agonist effect (i.e., half-maximal increases in 
[Ca2+]i) (EC50). Agonist efficacy was expressed as a 
percentage of the effect on [Ca2+]i observed with 100 µM 
mustard oil (MO). When significant, values of the effect on 
[Ca2+]i in wild-type (i.e., not transfected with any construct) 
HEK293 cells were taken as baseline and subtracted from the 
values obtained with transfected cells. Antagonist/ 
desensitising behavior was evaluated against 100 µM MO by 
adding test compound to the quartz cuvette 5 min before 
agonist stimulation. Data are expressed as the concentration 
exerting half-maximal inhibition of agonist-induced [Ca2+]i 
elevation (IC50), which was calculated using GraphPad 
Prism® software. The effect on [Ca2+]i exerted by MO alone 
was taken as 100%. Dose-response curves were fitted by a 
sigmoidal regression with variable slope. All determinations 
were performed at least in triplicate. Statistical analysis was 
performed by analysis of variance at each point using 
ANOVA followed by Bonferroni’s test. 
2.4. Animals  
 Male C57BL/6J mice, 8 weeks old (Harlan, Italy), were 
housed 5 per cage under controlled illumination (12:12 h 
light: dark cycle; light on 06.00 h) and standard 
environmental conditions (room temperature 22±1°C, 
humidity 60±10%) for at least one week before experimental 
use. Mouse chow and tap water were available ad libitum. 
Experimental procedures were in accordance with Italian and 
European regulations governing the care and treatment of 
laboratory animals (Permission no. 41/2007B). Animal care 
was in compliance with Ethical Guidelines of the IASP and 
European Community (E.C. L358/1 18/12/86) on the use and 
protection of animals in experimental research. All efforts 
were made to minimize animal suffering and to reduce the 
number of animals used.  
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2.5. Eye-Wiping Test 
 The pain-inducing potency of C1, C4, C10 and C11 was 
determined by the eye-wiping assay in mice, a sensitive 
animal model for acute trigeminal pain studies, using a 
protocol similar to that described in rats [28]. Male 
C57BL/6J mice were maintained in a controlled lighting 
environment and groups of 6-8 animals were used for each 
treatment. The animals received drug instillations (10 µl) in 
the left eye and were used for one treatment only. The 
number of eye-wiping movements following drug instillation 
into the eye was considered as an index of pungency. The 
eye-wiping reflexes in response to MO (10 µg/ml), or C1, 
C4, C10, C11 dropped in solution into the eye, was 
determined 10 min after the instillation. 
 In another set of experiments the effects of topical C4 
and C1 on MO-induced eye-wiping were studied. Mice were 
treated as follows: 
(A) MO (10 µg/ml) 
(B) C1 (10 µg/ml, 30 or 120 min) + MO (10 µg/ml)  
(C) C4 (10 µg/ml, 30 or 120 min) + MO (10 µg/ml)  
2.6 Formalin Test 
 Formalin injection induces a biphasic stereotypical 
nocifensive behavior [29]. Nociceptive responses are divided 
into an early, short-lasting first phase (0-7 min) caused by a 
primary afferent discharge produced by the stimulus, 
followed by a quiescent period and then a second, prolonged 
phase (15-60 min) of tonic pain. Mice received formalin 
(1.25 % in saline, 30 µl) in the dorsal surface of one side of 
the hindpaw. Each mouse was randomly assigned to one of 
the experimental groups and placed in a plexiglas cage and 
allowed to move freely for 30 min. A mirror was placed at a 
45-degree angle under the cage to allow full view of the 
hindpaws. Lifting, favoring, licking, shaking, and flinching 
of the injected paw were recorded as nociceptive responses. 
The duration of these noxious behaviors was monitored by 
an observer blind to the experimental treatment for periods 
of 0-10 min (early phase) and 20-60 min (late phase) after 
formalin administration. Groups of 6-8 animals per treatment 
were used with each animal being used for one treatment 
only. Mice received vehicle (5% dimethylsulfoxide in 0.9% 
NaCl) or different doses of C1, C4, C10 or C11 (0.75, 1.5 
and 3 µg/paw, 30 µl) administered 10 min before formalin or 
saline. 
3. RESULTS 
3.1. Effect of Chalcones on MO-Induced rat TRPA1-
Mediated Elevation of [Ca2+]i 
 We evaluated the possible inhibitory effect of chalcones 
on TRPA1-mediated [Ca2+]i elevation induced by 100 µM 
MO. Compounds were added 5 min before cell exposure to 
MO (Fig. 1). The observed inhibitory effect is likely due to 
desenitisation rather than antagonism, since: 1) chalcones 
per se added to cells produced a concentration-dependent 
increase in [Ca2+]i at concentrations similar to those 
necessary to inhibit the MO effect (Fig. 2), and 2) MO also 
inhibited its own effect when administered to cells in two 
consecutive times (IC50 1.71 ± 0.06 µM) [30]. The values of 
efficacy (expressed as % of MO) and potency (EC50) as well 
as the inhibition of increase in [Ca2+]i elevation induced by 
MO (IC50) are listed in Table 1. The four compounds with 
Table 1. Activity of Chalcones at rat TRPA1. Efficacy and Inhibition were Measured Versus 100 µM Mustard Oil (MO). 
O
R2R1
1
2
3
4
5
6
1
2
3
4
5
6
 
Code R1 R2 Ref. TRPA1 
    Efficacy (% MO 100µM) 
Potency µM  
(EC50) 
Inhibition µM (IC50) 
(vs MO 100µM) 
C1 3-NO2 4-OMe [21] 107.7 ± 1.7 0.70 ± 0.05 0.49 ± 0.01 
C2 4-Me H [22] 80.2 ± 3.3 1.4 ± 0.1 1.7 ± 0.1 
C3 H 4-OMe [23] 74.2 ± 2.9 2.3 ± 0.2 3.3 ± 0.2 
C4 3-NO2 H [24] 111.8 ± 1.6 0.27 ± 0.02 0.21 ± 0.01 
C5 H 4-OMe [25] 88.2 ± 1.4 1.6 ± 0.1 2.2 ± 0.1 
C6 4-OMe H [22] 69.3 ± 3.7 1.9 ± 0.2 2.3 ± 0.1 
C7 4-OMe 3-NO2 [26] 70.7 ± 1.5 0.94 ± 0.05 1.2 ± 0.1 
C8 4-OMe 4-OMe [23] 83.2 ± 5.7 10.6 ± 2.1 8.7 ± 1.1 
C9 H H [23] 108.1 ± 3.3 2.6 ± 0.3 2.1 ± 0.1 
C10 4-Cl 4-OMe [27] 92.5 ± 3.0 1.0 ± 0.1 0.82 ± 0.05 
C11 4-Cl H [22] 118.9 ± 4.2 1.4 ± 0.2 0.71 ± 0.04 
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IC50 below 1 µM were selected for testing in the eye-wiping 
and formalin assays in mice. 
 
 
 
Fig. (1). Dose-response effects of chalcones on the effect on 
intracellular Ca2+ in HEK-293-TRPA1 cells by 100 µM mustard oil 
(MO). Data are means ± SEM of n = 4 different determinations. 
 
 
 
Fig. (2). Dose-dependent effects of chalcones on elevation of 
intracellular calcium in HEK-293 cells overexpressing rat TRPA1. 
Data are means ± SEM of n = 4 different determinations. The 
compounds were tested also on HEK-293 cells not transfected with 
TRPA1: none produced a significant elevation of intracellular Ca2+. 
 
3.2. Effect of Topical MO and C1, C4, C10 and C11 on 
Eye-Wiping in Mice  
 The eye-wiping test was employed as an in vivo 
pungency test to assess the pain-producing effects of topical 
drugs. The instillation of 10 µl of allyl isothiocyanate 
solution (MO, 10 µg/ml), used as comparator drug, evoked 
28.9 ± 2.3 wiping movements monitored within 10 min. 
Moreover, we observed different pungency profiles for the 
various compounds tested. In particular, C10 proved to be 
the most pungent. No significant changes were seen 
following C10 topical application (10 and 30 µg/ml) as 
compared with MO. However, compounds C1, C4 and C11 
showed significantly lower pungent properties. In particular, 
the wiping movements were 8.7 ± 2.2 and 6.8 ± 2.9 for C1 
(10 and 30 µg/ml, respectively); 8.7 ± 2.3 and 5.8 ± 2.0 for 
C4 (10 and 30 µg/ml, respectively); and 25.2 ± 5.6 and 6 ± 
2.7 for C11 (10 and 30 µg/ml, respectively) (Fig. 3).  
 
3.3. Effect of Topical C4 and C1 on MO-Induced Eye-
Wiping in Mice 
 The two compounds with lowest eye-wiping activity, C1 
and C4, were also tested on MO (10 µg/ml) (Fig. 4) 
induction of such activity, given their TRPA1 desensitising 
activity in transfected HEK-293 cells. C4 pre-treatment (30 
and 120 min) significantly reduced (12.5 ± 3.2 and 11.6 ± 
4.0, respectively) the number of eye-wiping movements 
induced by application of MO (41.5 ± 2.8). Interestingly C1, 
applied 30 min before MO in the same eye, increased pain 
behavior (68.6 ± 11.0), although this was significantly 
decreased (10 ± 0.89) at 120 min in pre-treated mice, as 
compared to MO alone (33.2 ± 2.0). 
3.4. C1, C4, C10 and C11 Inhibit Formalin-Induced 
Nocifensive Behavior in Mice 
 The activity of compounds C1, C4, C10 and C11 was 
evaluated in the formalin test of acute peripheral and 
inflammatory pain in mice. Formalin-treated mice showed 
the typical nociceptive behavior characterized by an early, 
short-lasting first phase (0-7 min), followed by a quiescent 
period, and then a second, prolonged phase (15-60 min) of 
tonic pain [29]. Ten minutes before injection of formalin 
(1.25%, 30 µl), mice received intrapaw administration of 
vehicle or one of the four compounds (0.75, 1.5 and 3 µg/ 
30 µl). In spite of their diverse efficacies, all drugs exhibited 
antinociceptive activity in formalin-treated animals. In fact, 
we observed a significant dose-dependent reduction of both 
the first and the second phase of nocifensive response, as 
compared with vehicle-treated mice. Interestingly, C4-
mediated analgesic effects exhibited an inverted dose-
activity relationship, being most active at the lowest dose 
tested (0.75 µg/paw), but ineffective at the highest dose  
(Fig. 5).  
4. DISCUSSION 
 TRPA1 [31] is a polymodal nociceptor that detects 
noxious chemical agents, whether exogenous or produced 
endogenously during tissue injury, inflammation and 
oxidative stress [32, 33]. The structure of TRPA1 suggests 
that it functions as a sensitive, low-threshold electrophile 
receptor [34]. The contribution of TRPA1 to the initial phase 
of the inflammatory process and its participation in chronic 
inflammatory pain has been explored [35, 36]. Antagonists 
of this ion channel have the potential for treating neurogenic 
inflammatory conditions. TRPA1 is up-regulated following 
inflammatory injury [37], whereas in nerve endings TRPA1 
is activated by inflammatory mediators contributing to 
hyperalgesia [38]. Further, TRPA1 is a key molecular target 
in both neuropathic pain [39] and diabetic neuropathy [40, 
41]. In the current study, we demonstrate a potential novel 
mechanism of action for 11 compounds belonging to the 
chalcone family, i.e. their ability to mediate elevation of 
[Ca2+]i in HEK293-TRPA1 cells and subsequently desensitise 
TRPA1 in a heterologous expression system.  
 Four of the tested chalcone derivatives, C4, C1, C7 and 
C10 were more potent than mustard oil. At least four of the 
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Fig. (3). Effect of C1, C4, C10 and C11 (10 and 30 µg/ml) topical administration (10 µl) on the number of wiping movements into the left 
eye. Data are means ± SEM of n = 6-8 mice per group. Statistical significance was determined by one-way ANOVA, followed by Tukey’s 
post-hoc test. ***P<0.001 vs mustard oil-treated animals. 
 
 
 
Fig. (4). Effect of C1 or C4 (10 µg/ml) topical administration  
(10 µl) on the number of wiping movements induced by Mustard 
oil (MO, 10 µg/ml) into the left eye. C1 or C4 were applied 30 or 
120 min before mustard oil. Data are means ± SEM of n = 6-8 mice 
per group. Statistical significance was determined by One-way 
ANOVA followed by Tukey’s post-hoc test. *P<0.05 and 
***P<0.001 vs MO-treated animals. 
tested chalcones were significantly more potent at 
desensitising mustard oil than mustard oil itself. Unlike 
mustard oil, some chalcones were not pungent in the eye-
wiping assay, possibly due to their lipophilic nature. Indeed, 
several TRPV1 agonists which exhibit a slower onset of 
activation and high lipophilicity are also non-pungent [49-
52]. Although non-pungent per se, some chalcones inhibit in 
a long-lasting and dose-dependent manner the mustard oil-
induced response in the formalin test, likely due to TRPA1 
desensitisation to the action of mustard oil. The formalin test 
shows a biphasic pain-related behavior, with the first phase 
been attributed to TRPA1-mediated excitation of nociceptors, 
and the second phase to their inflammatory and/or spinal 
sensitisation. [53]. Either pharmacological blockade or 
genetic deletion of TRPA1 markedly reduces both the first 
and second phases of the nociceptive response induced by 
formalin in the rat and mouse paw [20]. The TRPA1 
antagonist HC-030031 inhibits the first phase of the formalin 
response, confirming a role for TRPA1 in this response [20].  
 At first glance these findings may appear difficult to 
rationalise given that chalcones activate TRPA1, a target of 
numerous hazardous/reactive chemicals such the pro-
nociceptive and pro-inflammatory agent mustard oil. The 
structurally similar compound, curcumin, a bis-α,β-
unsaturated β-diketone of two ferulic acid units connected 
through a methylene group, is a typical Michael acceptor 
[42]. Curcumin selectively activates and subsequently 
desensitises human [43] and rat TRPA1 in heterologous 
expression systems [44]. Curcumin has antioxidant, anti-
inflammatory, anticancer, antiviral, antibacterial, anti-
diabetic, anti-proliferative and pro-apoptotic properties, and 
clinical trials are underway to identify its potential beneficial 
effects [45]. Most of the these activities have been linked to 
curcumin’s α,β-unsaturated carbonyl moiety [46]. Curcumin 
inhibits the proliferation and survival of almost all types of
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(a) 
 
 
(b) 
 
Fig. (5). Effect of C1, C4, C10 and C11 (0.75, 1.5 and 3 µg/paw) in the formalin test in mice. The total time of the nociceptive response was 
measured every 5 min and expressed in minutes. Statistical significance was determined by two-way analysis of variance followed by 
Turkey-Kramer post-hoc test. *P<0.05 vs formalin+ vehicle-treated animals. 
 
tumour cells so far examined [47]. Its anti-inflammatory 
effects are mediated by suppression of the transcription 
factor NF-kB, which is activated in response to various 
carcinogens, growth factors and inflammatory cytokines 
[48]. It is worth noting that curcumin caused a strong 
desensitization and tachyphylaxis in a recombinant TRPA1 
system and may activate the channel efficaciously without 
producing noxious sensations. 
 These findings strongly suggest that chalcones can be 
considered as novel candidates for the development of anti-
hyperalgesic preparations based on TRPA1 desensitization. 
Indeed, the combination of significantly higher potency as a 
TRPA1-desensitizing agent and lower pungency should 
make these compounds useful tools for the treatment of 
neuropathic pain. In will be important in future studies to 
establish if chalcones are capable of producing anti-
hyperalgesic actions in animal models of chronic 
inflammatory and neuropathic pain. The present study 
already shows that intraplantar injection of some chalcones 
in mice not only fails to cause nociception but also inhibits 
the second phase of the nocifensive response to formalin, a 
widely used model of acute inflammatory pain. 
 Interestingly, the four most potent compounds at 
desensitising TRPA1 are chalcones with a substituent 
electron-acceptor in the B ring which is closer to the α,β-
unsaturated carbon, and whose nitro group is more efficient 
than a chlorine. The presence of a methoxy group in the 
other ring renders the compounds less active. This is in 
agreement with the hypothesis that the α-β-unsaturated 
ketone system in the structure of chalcones activates and 
desensitize TRPA1 via the formation of a covalent Michael 
adduct with cysteine residues within the channel [18, 19]. 
The IC50 rank is: 
C4 < C1 < C11 < C10 
 Although the presence of an electron-acceptor nitro 
group on the other ring does not appear to markedly impact 
TRPA1 agonist activity (EC50 C1 = 0.70±0,05 EC50 C7 = 
0.94±0.05), it approximately doubles the IC50 (IC50 C1 = 
0.49±0.01 IC50 C7 = 1.2±0.1). It is intriguing to note that a 
series of chalcone derivatives tested for their anti-
proliferative activities against a panel of cancer cells showed, 
in general, that compounds containing nitro groups on the 
ring near the α-β-unsaturation were more potent and 
selective [54]. 
 The importance of a nitro substituent in the ring for 
chalcone biological activity has been shown in vivo and in 
vitro. Chalcone derivatives with an electron-acceptor nitro 
group substituent in the A and B rings have anti-
hyperglycemic activity, increasing insulin secretion together 
with serum glucose-lowering in the presence of functional β 
cells. Only chalcones with a nitro group at position 3 on ring 
B, the same position as our C4, showed significant and acute 
anti-hyperglycemic activity in short-term treatment, in 
contrast to when the electron-acceptor nitro group is at 
position 2’ in ring A [55]. Indeed, TRPA1 is abundantly 
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expressed in a rat pancreatic β cell line, and its activation by 
endogenous and exogenous ligands stimulates insulin release 
[56]. Chalcones are being considered for the management 
not only of diabetes but also treatment of several pathologies 
[3, 57]. A series of chalcone derivatives (curcumin analogs) 
showed anti-inflammatory activity in mouse RAW 264.7 
macrophages, inhibiting the lipopolysaccharide-induced 
expression of tumour necrosis-α and interleukin-6 [58]. 
Structure-activity studies show that the asymmetric compounds 
possessed higher anti-inflammatory activity, while electro-
negativity was an important factor for inhibiting 
lipopolysaccharide-induced interleukin-6 expression. Some 
nitro-substituted chalcones have also been proposed for the 
treatment of neurodegenerative diseases such as 
parkinsonian syndromes [59]. 
5. CONCLUSION 
 Eleven compounds, belonging to the chalcone family, 
were able to desensitise TRPA1. Several were not pungent in 
the eye-wiping assay and quite remarkably inhibited, in a 
long-lasting and dose-dependent manner the mustard oil-
induced response in the formalin test. Chalcones can be 
considered as novel candidates for the development of anti-
hyperalgesic preparations based on TRPA1 desensitization. 
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